Key Points Regeneron's stock has underperformed the market this year, but it got a boost last time it reported earnings. The company's revenue grew by 17% last quarter, and multiple drugs hit all-time highs. The stock trades at a low earnings multiple when compared to the S&P 500 average. 10 stocks we like better than Regeneron Pharmaceuticals › Regeneron Pharmaceuticals' (NASDAQ:REGN) stock is having an underwhelming year, down around 1% thus far. It's been a quality growth stock to own for the long haul, and with some terrific assets in its portfolio, it has the potential to perform much better in the long run. Next month, on Oct. 30, it will release its third-quarter earnings results.
We show the main point publicly. Create a free account to continue reading the full article, save it, discuss it, and connect it with market and OSINT context.